Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 1 of 27
                                                        Vers ion 1.0, 26APR2018  
 
 
TITLE PAGE  
 
 
 
 
Protocol Number:  C-18-TS18 
Protocol Title:  Multi -Center Pi[INVESTIGATOR_709197]:  
 Cutera, Inc.  
[ADDRESS_964183]  
Brisbane, CA [ZIP_CODE] Telephone: 408- 207- [ADDRESS_964184]: Minda Seal 
Email: mseal @cutera.com  
 
 
Version, Date:  Version 1, Dated April 26, [ADDRESS_964185] their origin in the Declaration of Helsinki, and that are consistent with Good Clinical Pra ctice (GCP) and the applicable regulatory requirement(s).  
    
NOTE:   The confidential information in the following document is provided to you as an Investigator, potential Investigator, or 
consultant for review by [CONTACT_10825], your staff, and applicable Institutional Review Board. By [CONTACT_11217], you agree that 
the information contained herein will not be disclosed to others, without written authorization from Cutera, Inc. except to t he 
extent necessary to obtain informed consent from those persons to whom the device will be administered.  
  
Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 2 of 27
                                                        Vers ion 1.0, 26APR2018 Protocol Signature [CONTACT_3490] – Principal Investigator  
 
 
[INVESTIGATOR_11208] C -18-TS18 
 
 
Study Title:   Multi -Center Pi[INVESTIGATOR_57827] [ADDRESS_964186], except 
those changes necessary to eliminate apparent immediate hazards to subjects.  I will provide copi[INVESTIGATOR_709198]. I will discuss th is material with them and ensure they are fully informed regarding their role in the study. I will ensure that 
the study is conducted in compliance with the protocol, Good Clinical Practice (GCP), and all applicable 
regulatory requirements, and with t he reviewing Institutional Review Board (IRB) requirements. I agree 
to commence this study only after documented IRB approval is obtained.  
 
 
 
 
Principal 
Investigator      
  [INVESTIGATOR_57829], Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge [ADDRESS_964187] Discontinuation Criteria  
6 STUDY  PROCEDURES  10 
6.1 Screening and Enrollment Visit Procedures  10 
6.2 Pre-Treatment Procedures and  Treatment Visits  11 
    6.3      Follow -up Visit  
7 ADVERSE  EVENTS  AND ADVERSE  DEVICE  EVENTS  12 
7.1 Definitions  12 
7.1.1 Adverse Event (AE)  12 
7.1.2 Serious Adverse Event (SAE)  [ADDRESS_964188] (ASADE)  [ADDRESS_964189] ([LOCATION_003]DE)  12 
7.2 Recording AEs/ADEs and SAEs/SADEs  14 
7.3   Follow -up of Subjects after A Es 14 
8 POTENTIAL  RISKS  / BENEFITS  14 
8.1 Po
tential Risks  14 
Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 4 of 27
                                                        Vers ion 1.0, 26APR2018 8.2 Potential Benefits  15 
9 DATA  ANALYSIS  PLAN  16 
9.1 Sample Size  16 
9.2 Analysis  Sets 16 
9.3 Analysis of Exploratory/ Efficacy Endpoints  [ADDRESS_964190] Confidentiality  18 
10.6 Publication Policy  18 
REFERENCES  19 
Appendix 1: Study Schedule  21 
Appendix 2: Pain Rating Scale                                                                                                                                    22 
Appendix 3: Before and After Treatment Instructions                                                                                          23 
Appendix 4: Subject Questionnaire                                                                                                                         24 
Appendix 5: Global Aesthetic Improvement Scale  (GAIS)                                                                                     26 
Appendix 6: Investigator Evaluation                                                                                                                        27  
 
  
Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge [ADDRESS_964191] s may also be recruited from the 
Investigator’s existing patient database or from patients who present themselves to the study site 
requesting treatment. Only subject s who meet all eligibility criteria and who provide written informed 
consent will be enrolled into the study.  
 
Each subject  will be evaluated by [CONTACT_57839]/her suitability for entry into the study 
accord ing to the following inclusion and exclusion criteria.  
5.1.[ADDRESS_964192] meet all of the following Inclusion Criteria:  
 
1.  Subject must be able to read, understand and sign the Informed Consent Form.  
2.  Female or Male, 18 to 65 years of age (inclusive).  
3.  Subject h as visible fat bulges in the area to be treated.  
4.  Non-smoking for at least [ADDRESS_964193] agree to not undergo any other proced ure(s)  in the treatment  region 
during the study period.  
6.  Subject must adhere to the follow -up schedule and study instructions . 
7.  Subject must adhere to the same diet and/or exercise routine throughout the study, 
and agree to maintain the same weight throughout the study . 
8.  Willing to have photographs taken of the treatment area and agree to use of 
photographs for presentation, (educational and/or marketing), publications, and any 
additional marketing purposes.  
9.  For female subjects: not pregnant or la ctating and is either post -menopausal, surgically 
sterilized, or using a medically acceptable form of birth control prior to enrollment and 
during the entire course of the study.  
5.1.2 Exclusion Criteria  
Subjects will be excluded from the study if they meet any  of the following Exclusion Criteria:  
1.  Participation in a clinical trial of another device or dru g within 1 month  of study 
participation, or during the study period.  
2.  Any type of prior cosmetic treatm ent to the target area within 6  months of study 
partici pation . 
3.  Any prior invasive cosmetic surgery to the target area, such as liposuction.  
4.  Has a pacemaker, internal defibrillator, implantable cardioverter -defibrillator, nerve 
stimulator implant, cochlear implant or any other electronically, magnetically or 
mechanically activated implant.  
5.  Has metal implan t(s) within the body, such as  artificial he art valves.  
Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge [ADDRESS_964194] unsuitable for inclusion . 
7.  History of any disease or condition that could impair wound healing.  
8.  History of keloid formation, hypertrophic scarring or abnormal/delayed wound healing.  
9.  Skin abnormality in the t reatment  area that in the opi[INVESTIGATOR_709199] . 
10.  Currently undergoing systemic chemotherapy or radiation treatment for cancer, or 
history of treatment in the target area within 3 months of study participation.  
11.  Allergy or sensitivity to Tegaderm.   
12.  As per the Investigator’s discretion, any physical or mental condition which might make 
it unsafe for the subjec t to participate in this study or a condition that would 
compromise the subject’s ability to comply with the study requirements.  
 
5.[ADDRESS_964195] identification number. This number is comprised 
of a site number (which is provided by [CONTACT_456]) and a sequential subject number and the subject 
initials (first and last names).  
5.2.[ADDRESS_964196]’s continued medical care in any way. In those instances, the investigator will attempt to obtain a final clinical assessment and an adverse device effect evaluation for the subject prior to this withdrawal. A subject will be considered 
lost to follow -up only after three unsuccessful, documented attempts to contact [CONTACT_57840].    
In addition, a subject can be discontinued for any of the following reasons: the Principal Investigator 
[INVESTIGATOR_57834]’s best interest, a subject is 
noncompliant with the protocol, a subject has a serious reaction to the treatment, a subject develops 
any of the exclusion criteria during the study period or the study is stopped by [CONTACT_4530].  
 
6 STUDY
 PROCEDURES 
 
  
 
 
 
 
   

Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 21 of 27
                                                        Vers ion 1.0, 26APR2018 

Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 22 of 27
                                                        Vers ion 1.0, 26APR2018  
 
 
  
 
 
 
  
 
 
 
  
 
 
 
 
 

Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 24 of 27
                                                        Vers ion 1.0, 26APR2018 

Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 25 of 27
                                                        Vers ion 1.0, 26APR2018  
 
 
         
 
          
 
    
 
 
  
 

Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 26 of 27
                                                        Vers ion 1.0, 26APR2018 Appendix 5  
 
Week 12 -Investigator Global Aesthetic Improvement Scale (GAIS):  Compared to Baseline Photos  
  
0 No Change  
+1 Mild Improvement  
+2 Moderate Improvement  
+3 Significant Improvement  
 
 
      
 
          
 
         
 
  
 
Cutera, Inc.  
Protocol # C -18-TS18 
“Multi -Center Pi[INVESTIGATOR_709196]” 
 
Confidential and Propr ietary                                              Pa ge 27 of 27
                                                        Vers ion 1.0, 26APR2018 
